Vericel Corporation (VCEL) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $35.19 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: Matricel GmbH; Earnings in 6 days (event risk).
Vericel Corporation markets two FDA-approved autologous cell therapies (MACI for knee cartilage repair, Epicel for severe burns) and one specialty biologic (NexoBrid for eschar removal) in the U.S. Revenue comes from direct sales to hospitals and specialty pharmacy distributors... Read more
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $35.19 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: Matricel GmbH; Earnings in 6 days (event risk). Chart setup: Death cross but MACD improving, RSI 52. Score 5.2/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierMatricel GmbH10-K Item 1A: 'Failure of third parties, including, for example, Matricel GmbH ("Matricel"), to manufacture or supply certain components ... would impair our cell product development and commercialization'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $35.19 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: Matricel GmbH; Earnings in 6 days (event risk). Chart setup: Death cross but MACD improving, RSI 52. Prior stop was $32.73. Score 5.2/10, moderate confidence.
Take-profit target: $47.48 (+34.9% upside). Prior stop was $32.73. Stop-loss: $32.73.
Concentration risk — Supplier: Matricel GmbH; Earnings in 6 days (event risk); Negative momentum.
Vericel Corporation trades at a P/E of 108.5 (forward 43.1). TrendMatrix value score: 4.3/10. Verdict: Sell.
14 analysts cover VCEL with a consensus score of 4.2/5. Average price target: $55.
What does Vericel Corporation do?Vericel Corporation markets two FDA-approved autologous cell therapies (MACI for knee cartilage repair, Epicel for...
Vericel Corporation markets two FDA-approved autologous cell therapies (MACI for knee cartilage repair, Epicel for severe burns) and one specialty biologic (NexoBrid for eschar removal) in the U.S. Revenue comes from direct sales to hospitals and specialty pharmacy distributors serving sports medicine and burn care markets.